The latest funding rounds, like Secretome Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
Secretome Therapeutics raises $30 million in Series A financing from RA Capital Management to advance STM-01 for Duchenne-associated cardiomyopathy.
PRIVATEMay 27, 2026•27 days ago
Amount Raised
$30 Million
Round Type
series a
BaltimoreBiotechnology
Investors
Ra Capital Management
Description
Secretome Therapeutics has closed a $30 million Series A financing from RA Capital Management to support the advancement of STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy. This funding will help develop their neonatal cardiac progenitor cell platform further. David Lubner has joined the Board of Directors as part of the financing. The funds will facilitate pivotal Phase 2 and Phase 3 trials for STM-01.
Company Information
Company
Secretome Therapeutics
Location
323 W Camden St, Suite 600
Baltimore, Maryland, United States
About
Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and our pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.
BaltimoreBiotechnology